New Risk • Apr 04
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Revenue is less than US$1m (UK£25k revenue, or US$33k). Market cap is less than US$10m (UK£5.69m market cap, or US$7.51m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Announcement • Apr 02
CRISM Therapeutics Corporation Announces Board and Committee Changes CRISM Therapeutics Corporation announces that Dr. Nermeen Varawalla has resigned from the Board of Directors in order to pursue other professional interests. Nermeen was appointed Non-Executive Chair at the Company's Admission to AIM in May 2024 and, as previously announced, in October 2025 stepped back from her role. Andrew Webb will continue to act as Executive Chair on an interim basis until a new Chair is identified. Gerry Beaney, Independent Non-Executive Director and Chair of the Audit Committee will chair the Remuneration Committee. Announcement • Mar 26
CRISM Therapeutics Corporation Provides Phase 2 Clinical Trial Progress Update For Irinotecan-ChemoSeed In Glioblastoma CRISM Therapeutics Corporation provided a progress update on its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma. The Company confirmed that its US-based contract development and manufacturing organisation, ProMed Pharma LLC, has successfully manufactured the first clinical batch of ChemoSeed in accordance with current Good Manufacturing Practice standards. The batch will now undergo sterilisation and release testing, making it ready for use in the Phase 2 trial. The Company also continues to work closely with its contract research organisation, Aixial, and the first clinical trial site, to complete the remaining site activation steps so as to commence patient dosing. Although progress toward trial commencement is moving at pace, the exact timing of first patient dosing is difficult to anticipate. As such, the Company is extending guidance on the timing of first patient dosing to H1 2026. The Company remains focused on initiating the trial shortly and will provide further updates on the commencement of the trial as soon as possible. New Risk • Feb 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Revenue is less than US$1m (UK£25k revenue, or US$34k). Market cap is less than US$10m (UK£6.47m market cap, or US$8.83m). New Risk • Jan 06
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 58% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Revenue is less than US$1m (UK£25k revenue, or US$34k). Market cap is less than US$10m (UK£5.56m market cap, or US$7.52m). Minor Risk Share price has been volatile over the past 3 months (9.9% average weekly change). Announcement • Dec 16
CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.05961 million. CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.05961 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 662,332
Price\Range: £0.09 Announcement • Dec 12
CRISM Therapeutics Corporation has filed a Follow-on Equity Offering in the amount of £0.1 million. CRISM Therapeutics Corporation has filed a Follow-on Equity Offering in the amount of £0.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,111,111
Price\Range: £0.09 Announcement • Dec 11
CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £1 million. CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 11,111,112
Price\Range: £0.09
Security Features: Attached Warrants
Transaction Features: Subsequent Direct Listing New Risk • Dec 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (UK£25k revenue, or US$33k). Market cap is less than US$10m (UK£3.50m market cap, or US$4.66m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). Announcement • Oct 14
CRISM Therapeutics Corporation Announces Positive Preclinical Data in Prostate Cancer and Prestative Doctoral Award CRISM Therapeutics Corporation announced significant preclinical findings and a new research collaboration that mark key milestones in the development of its innovative ChemoSeed platform in prostate cancer. Prostate cancer, the most prevalent cancer in men, is the second programme in CRISM's pipeline of product opportunities using the implantable ChemoSeed drug delivery platform. The Company's most advanced programme, irinotecan-ChemoSeed in glioblastoma, remains on track for the first patients to be dosed in an open label Phase 2 clinical trial in early 2026. In vitro studies conducted by CRISM Therapeutics have demonstrated that the sustained administration of docetaxel to prostate cancer cell lines is significantly more effective than the intermittent dosing schedules currently used in the standard of care. Sustained administration killed 72% of the prostate cancer cells compared with 65% with intermittent dosing. Furthermore, the concentration of docetaxel needed to inhibit 50% (IC 50) of prostate cancer cells from growing was 3.5nM for sustained administration compared with 9.8nM for intermittent dosing. The lower the IC 50, the more potent the treatment. Finally, at lower doses sustained administration of docetaxEL resulted in continued reduction of prostate cancer cells for 12 days, whereas with intermittent dosing there was less reduction in the prostate cancer cells and the cells started to regrow by day 9. These findings strongly support the hypothesis that sustained, localised delivery of chemotherapy, enabled by CRISM's proprietary ChemoSeed Drug delivery platform, could substantially enhance the efficacy of docetaxel, a generic chemotherapy drug, in the treatment of prostate cancer. Furthermore, with ChemoSeed this increase in efficacy could be achieved with lower amounts of docetaxel being given to the patient reducing the unwanted side effects typically seen with this drug. In addition, CRISM has successfully formulated docetaxel within the ChemoSeed platform, achieving sustained drug release over a period of at least 28 days. This major technical milestone confirms the feasibility of using ChemoSeed for prolonged, controlled delivery of docetaxel directly into prostate tumours, addressing a major limitation of current systemic chemotherapy approaches. Further strengthening its R&D capabilities, CRISM announced it has been awarded a prestigious Department for the Economy ("DfE") Collaborative Doctoral Partnership ("CDP") studentship in collaboration with Ulster University. This partnership will support the ongoing development of docetaxel-ChemoSeed and explore its application in the personalised treatment of prostate cancer, including potential patient-specific dosing strategies and tumour-targeting delivery models. The data clearly suggest that delivering chemotherapy locally and continuously, rather than intermittently and systemically, could provide a much-needed improvement in therapeutic efficacy. The partnership with Ulster University will further accelerate the progress and help bring this innovative treatment to patients faster. Announcement • Sep 12
CRISM Therapeutics Corporation to Report Q2, 2025 Results on Sep 15, 2025 CRISM Therapeutics Corporation announced that they will report Q2, 2025 results on Sep 15, 2025 Board Change • Sep 08
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Chief Scientific Officer & Executive Director Chris McConville is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Sep 01
CRISM Therapeutics Corporation Receives Regulatory and Ethical Approval for Registration-Grade Phase 2 Trial of Irinotecan-ChemoSeed in Glioblastoma CRISM Therapeutics Corporation confirmed that it has received both regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and favourable ethical opinion from a UK Research Ethics Committee (REC) to initiate its open label registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™? in patients with surgically resectable glioblastoma. This dual approval marks a significant operational milestone and clears the Company to commence the trial across selected UK clinical sites in first quarter of 2026, as planned. The approved study, titled "An Open-label Phase 2 Safety and Efficacy Trial of Irinotecan ChemoSeed Administered Directly into the Resection Margin in Patients with Surgically Resectable Glioblastoma", is designed to assess the safety, tolerability, and efficacy of irinotec an-ChemoSeed, CRISM's proprietary, biodegradable implant technology delivering sustained-release irinotecan directly into the tumour resection margin following surgical removal of the glioblastoma tumour. The trial has been designed in alignment with regulatory expectations for future marketing authorisation submissions. Key Highlights: Regulatory (MHRA) and Ethical (REC) approval received; Trial confirmed to initiate in first quarter of 2026 at leading UK neuro-oncology centres; Open-label format supports interim analysis, reporting of early results and potential for expedited regulatory approval; ChemoSeed platform targets local recurrence with sustained, localised chemotherapy; Registration-grade Phase 2 design supports pathway to marketing authorisation and commercialisation. CRISM is working with its CRO, Aixial Group, to activate the first site in the UK and start to enrol patients in first quarter of 2026. Further details of the trial are included in the Submission of Clinical Trial Authorisation application to the MHRA announcement on 01 July 2025. Announcement • Aug 13
CRISM Therapeutics Announces GMP Manufacture of ChemoSeed for Phase 2 Clinical Trial in Glioblastoma CRISM Therapeutics announced the initiation of production of a clinical batch of ChemoSeed, its proprietary sustained-release implant containing irinotecan, under Good Manufacturing Practice (GMP). This clinical batch will be produced for the Company's upcoming open-label Phase 2 safety and efficacy trial evaluating ChemoSeed administered directly into the resection margin in patients with surgically resectable glioblastoma. US-based ProMed Pharma LLC, a Contract Development and Manufacturing Organisation ("CDMO"), will produce the clinical batch. The start of production marks a critical step toward first patient dosing, expected in First Quarter 2026, and underscores CRISM's commitment to addressing the significant unmet need in glioblastoma, a highly aggressive brain cancer with poor prognosis and limited effective treatment options. The Phase 2 study is designed to evaluate both safety and efficacy following direct administration of ChemoSeed into the tumour resection margin, with the goal of delivering a local high-dose of chemotherapy over a sustained period of time, while minimising systemic toxicity. This innovative approach builds on positive preclinical and early clinical data and has the potential to redefine the standard of care in post-surgical glioblastoma management. Announcement • Aug 05
CRISM Therapeutics Corporation, Annual General Meeting, Aug 26, 2025 CRISM Therapeutics Corporation, Annual General Meeting, Aug 26, 2025. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom Announcement • Jul 04
CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.054021 million. CRISM Therapeutics Corporation has completed a Follow-on Equity Offering in the amount of £0.054021 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 450,176
Price\Range: £0.12 Announcement • Mar 31
CRISM Therapeutics Corporation Provides Positive Update Regarding Its Clinical Trial Authorisation Application CRISM Therapeutics Corporation provided a positive update regarding its clinical trial authorisation application to evaluate irinotecan ChemoSeed in patients with high grade glioma. CRISM has been working with the Medicines and Healthcare products Regulatory Agency to finalise the design of the first in-human trial of ChemoSeed and is pleased to confirm it has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed. The written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately PS400,000 to conduct the toxicology studies. In addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in first quarter 2025 and to begin clinical trials of ChemoSeed in fourth quarter 2025, subject to MHRA and other external regulatory organizations meeting expected review times. The Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify. Announcement • Mar 28
CRISM Therapeutics Corporation Announces Grant Awarded by Innovate UK CRISM Therapeutics Corporation announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the "Project"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas. The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology ("docetaxel ChemoSeed") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment. Docetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect. The Project, which will take about 12 months, is designed to deliver: A functional prototype of the implantable device; Pre-clinical validation data demonstrating safety and efficacy; IP protection through patents for core innovations; Scalable manufacturing protocols for commercialisation. The outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy. The total cost of the Project is £152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of £96,106, which represents 63% of the total cost. The remaining £56,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed. Announcement • Sep 09
CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024 CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024 Announcement • May 15
Amur Minerals Corporation, Annual General Meeting, May 29, 2024 Amur Minerals Corporation, Annual General Meeting, May 29, 2024. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom Announcement • Nov 13
Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023 Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023, at 10:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom Announcement • Sep 25
Amur Minerals Corporation Announces Special Dividend Amur Minerals Corporation announced to pay a one-time special dividend of 1.8 pence per ordinary share within 90 days of receipt of the completion payment. Announcement • Sep 07
Amur Minerals Announces Suspension of Trading on AIM Amur Minerals Corporation confirmed that trading in the Company's shares on AIM will be suspended with effect from 7.30 a.m. BST 7 September 2023. As stated in the Company's notification of 6 March 2023, following the disposal of the Company's AO Kun-Manie subsidiary, Amur became classified as an AIM Rule 15 cash shell from that date, and as such was required to make an acquisition or acquisitions which would constitute a reverse takeover under Rule 14 of the AIM Rules for Companies, or be re-admitted on AIM as an investing company under the AIM Rules on or before the date falling six months from 6 March 2023. As neither a reverse takeover nor readmission to trading on AIM as an investing company have been completed, trading in the Company's shares on AIM will now be suspended on7 September 2023. Trading will remain suspended until the completion of a reverse takeover, which requires the publication of an admission document and the approval of such a transaction at a General Meeting of the Company, or the Company is readmitted to trading on AIM as an investing company. If no such transaction is completed within six months, the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41. There can be no assurance that the Company will be able to complete a reverse takeover during the six-month suspension period. The board of Amur continues to review a number of reverse takeover opportunities. Further announcements will be made as appropriate. Announcement • Aug 10
Amur Minerals Corporation Announces Cessation of Discussions with Ascent Resources Plc Ascent Resources Plc (AIM:AST) ("Ascent" or, the "Company"), noted Amur Minerals Corporation (AIM:AMC) ("Amur") announcement, regarding the cessations of discussions regarding thenon-binding indicative proposal of a possible share offer for the entire issued and to be issued share capital of Amur by Ascent. Ascent is surprised and disappointed with this announcement given the last communication between the parties was three weeks ago with Ascent confirming its forward process and timetables to achieve the possible combination, following which Ascent has been waiting for the Amur board to engage further on the proposal. Given that Ascent is expecting imminently the result of its €3.5 million+ arbitration claim against its JV partner in Slovenia, Ascent still believes that a combination of the two companies would be in the interest of both shareholder groups. Accordingly, Ascent is exploring the possibility to put forward a binding offer to the shareholders for the issued and to be issued share capital of Amur. Announcement • Jun 02
Ascent Resources Announces Intention to Bid for Amur Minerals The board of directors of Ascent Resources Plc (AIM:AST) announced their intention to bid for the entire issued and to be issued share capital of Amur Minerals Corporation (AIM:AMC) following a period of protracted discussions with the Board of Amur. Ascent's vision is that Ascent and Amur would combine to form a larger, well funded and more liquid, entity combining Amur's cash (post the recently announced asset sale and subsequent dividend) with Ascent's ESG Metals project pipeline in LATAM, which typically have low geological risk and near term and sustainable cashflows, in addition to the significant upside exposure of Ascent's funded EUR 500+ million Energy Charter Treaty damages claim(the "Potential Combination"). Ascent submitted a non-binding indicative proposal to the Board of Amur in November 2022 to acquire 100% of the issued and to be issued share capital of Amur (post payment of its dividend as subsequently announced 24 May 2023) in a share-for-share exchange on a ratio of approximately 1 new Ascent share for every 21 Amur shares in issue (the "Exchange Ratio") (subject to the reservations set out below) (the "Indicative Proposal"). On the assumption that Amur only has assets of $5,000,000 in cash (post payment of dividend) and no further material liabilities, the indicative proposal is equivalent to a gross equity valuation of 6.1 pence per new Ascent share (based on an exchange rate of $1 = £0.8051). Despite multiple conversations with the Board of Amur and multiple follow up correspondence, the Company has as yet been unable to elicit a written response to their offer. The Indicative Proposal also included the intention to combine the skills of both executive teams, as well as other potential changes to the enlarged groups non-executive directors. It is intended that the enlarged group would have a majority of board directors from Ascent. The Exchange Ratio, based on Ascents volume weighted average share price of 3.6716 pence yesterday, being the last business day immediately prior to the date of this announcement, currently represents a value of approximately 0.175 pence per Amur share. At the current value of approximately 0.175 pence per Amur share implied by the Exchange Ratio, a potential offer, if made, when added to the 1.8 pence dividend to be paid by Amur would represent a premium of approximately: 7.3%. to the Amur closing price of 1.840 pence per share on 31 May 2023, being the last business day immediately prior to this announcement; 15.3%. to the monthly average volume weighted average price calculations for Amur shares over the three-month period starting on and including 1 March 2023, being 1.713 pence per share; and 47.5%. to the monthly average volume weighted average price for Amur shares over the six-month period starting on and including 1 December 2022, being 1.339 pence per share Under the terms of the Indicative Proposal, it is expected that Amur shareholders would own approximately 28.6%. of the enlarged group, and Ascent shareholders would own approximately 71.4%. of the enlarged group. Given the Indicative Proposal is currently proposed to be structured as an share-for-share exchange effected by either scheme of arrangement or plan of arrangement, Ascent is currently only minded to proceed with the Indicative Proposal on the pre-condition that a recommendation from the Amur Board is ultimately forthcoming. Announcement • May 25
Amur Minerals Corporation Announces Special Dividend, Payable on June 14, 2023 Amur Minerals Corporation provide an update on the issuance of its special dividend of 1.8 pence per share. The special dividend is to be paid out of the funds received for the sale of its Russian Federation Kun-Manie nickel -copper asset. As the funds have been sourced from a non-sanctioned entity in Russia, payment of the dividend has required extraordinary non-typical enhanced governance approaches for implementation of payment. Shareholders of record at the close of business 2 June 2023 will be entitled to payment of the dividend projected to be 14 June 2023. The shares will go ex-dividend on 1 June 2023. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Tom Bowens was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Tom Bowens was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 
